SAB BIO to Participate in Upcoming Investor Conferences
Rhea-AI Summary
SAb Biotherapeutics (Nasdaq: SABS) announced that members of management will participate in three investor conferences in November–December 2025: a UBS Global Healthcare Conference fireside chat on Nov 10, 2025 at 2:45 p.m. ET in West Palm Beach, a Guggenheim Healthcare Innovation Conference fireside chat on Nov 12, 2025 at 10:00 a.m. ET in Boston, and an Evercore Healthcare Conference fireside chat on Dec 2, 2025 at 3:50 p.m. ET in Coral Gables.
Live webcasts and archived recordings will be available on the company Investor Relations Events page at www.sab.bio.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, SABS declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for autoimmune diseases, including its lead program in clinical development for delaying the progression of type 1 diabetes (T1D) in new onset Stage 3 patients, today announced that members of its management team will participate in the following investor conferences this November and December:
UBS Global Healthcare Conference
Date: November 10, 2025
Time: 2:45 p.m. ET
Format: Fireside Chat
Location: West Palm Beach, FL
Guggenheim Second Annual Healthcare Innovation Conference
Date: November 12, 2025
Time: 10:00 a.m. ET
Format: Fireside Chat
Location: Boston, MA
8th Annual Evercore Healthcare Conference
Date: December 2, 2025
Time: 3:50 p.m. ET
Format: Fireside Chat
Location: Coral Gables, FL
To access the live webcasts of these events, as well as archived recordings, please visit the Investor Relations/Events section of the Company’s website at www.sab.bio.
About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary platform which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. For more information, visit www.sab.bio.
CONTACTS
Investors:
Cristi Barnett
ir@sab.bio
Media:
Sheila Carlson
media@sab.bio
FAQ
When will SAb Biotherapeutics (SABS) present at the UBS Global Healthcare Conference?
How can investors watch SAb Biotherapeutics (SABS) presentations from November–December 2025?
What time is the SAb Biotherapeutics (SABS) fireside chat at the Guggenheim Healthcare Innovation Conference?
When and where is SAb Biotherapeutics (SABS) speaking at the Evercore Healthcare Conference?
Will SAb Biotherapeutics (SABS) provide replay access for its November–December 2025 conference presentations?
